119 related articles for article (PubMed ID: 16501603)
1. Expression of GCIP in transgenic mice decreases susceptibility to chemical hepatocarcinogenesis.
Ma W; Xia X; Stafford LJ; Yu C; Wang F; LeSage G; Liu M
Oncogene; 2006 Jul; 25(30):4207-16. PubMed ID: 16501603
[TBL] [Abstract][Full Text] [Related]
2. GCIP/CCNDBP1, a helix-loop-helix protein, suppresses tumorigenesis.
Ma W; Stafford LJ; Li D; Luo J; Li X; Ning G; Liu M
J Cell Biochem; 2007 Apr; 100(6):1376-86. PubMed ID: 17131381
[TBL] [Abstract][Full Text] [Related]
3. Dual functions of E2F-1 in a transgenic mouse model of liver carcinogenesis.
Conner EA; Lemmer ER; Omori M; Wirth PJ; Factor VM; Thorgeirsson SS
Oncogene; 2000 Oct; 19(44):5054-62. PubMed ID: 11042693
[TBL] [Abstract][Full Text] [Related]
4. A novel senescence-evasion mechanism involving Grap2 and Cyclin D interacting protein inactivation by Ras associated with diabetes in cancer cells under doxorubicin treatment.
Lee I; Yeom SY; Lee SJ; Kang WK; Park C
Cancer Res; 2010 Jun; 70(11):4357-65. PubMed ID: 20460530
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor promotes hepatocarcinogenesis through c-Met autocrine activation and enhanced angiogenesis in transgenic mice treated with diethylnitrosamine.
Horiguchi N; Takayama H; Toyoda M; Otsuka T; Fukusato T; Merlino G; Takagi H; Mori M
Oncogene; 2002 Mar; 21(12):1791-9. PubMed ID: 11896611
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte-specific activation of NF-kappaB does not aggravate chemical hepatocarcinogenesis in transgenic mice.
Yau TO; Chan CF; Gee-San Lam S; Cheung OF; Ching YP; Jin DY; Sham MH; Ng IO
J Pathol; 2009 Feb; 217(3):353-61. PubMed ID: 19090486
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of mutant frequencies of chemically induced tumors and normal tissues in lambda/cII transgenic mice.
Mirsalis JC; Shimon JA; Johnson A; Fairchild D; Kanazawa N; Nguyen T; de Boer J; Glickman B; Winegar RA
Environ Mol Mutagen; 2005; 45(1):17-35. PubMed ID: 15605353
[TBL] [Abstract][Full Text] [Related]
8. The five amino acid-deleted isoform of hepatocyte growth factor promotes carcinogenesis in transgenic mice.
Bell A; Chen Q; DeFrances MC; Michalopoulos GK; Zarnegar R
Oncogene; 1999 Jan; 18(4):887-95. PubMed ID: 10023664
[TBL] [Abstract][Full Text] [Related]
9. Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats.
Dragan YP; Sargent LM; Babcock K; Kinunen N; Pitot HC
Mol Carcinog; 2004 Jul; 40(3):150-9. PubMed ID: 15224347
[TBL] [Abstract][Full Text] [Related]
10. Collaboration between growth factors and diverse chemical carcinogens in hepatocarcinogenesis of transforming growth factor alpha transgenic mice.
Takagi H; Sharp R; Takayama H; Anver MR; Ward JM; Merlino G
Cancer Res; 1993 Sep; 53(18):4329-36. PubMed ID: 8364928
[TBL] [Abstract][Full Text] [Related]
11. Delayed liver regeneration and increased susceptibility to chemical hepatocarcinogenesis in transgenic mice expressing a dominant-negative mutant of connexin32 only in the liver.
Dagli ML; Yamasaki H; Krutovskikh V; Omori Y
Carcinogenesis; 2004 Apr; 25(4):483-92. PubMed ID: 14688024
[TBL] [Abstract][Full Text] [Related]
12. Ribosomal phosphoprotein P0 interacts with GCIP and overexpression of P0 is associated with cellular proliferation in breast and liver carcinoma cells.
Chang TW; Chen CC; Chen KY; Su JH; Chang JH; Chang MC
Oncogene; 2008 Jan; 27(3):332-8. PubMed ID: 17621266
[TBL] [Abstract][Full Text] [Related]
13. The mouse equivalent of the human p53ser249 mutation p53ser246 enhances aflatoxin hepatocarcinogenesis in hepatitis B surface antigen transgenic and p53 heterozygous null mice.
Ghebranious N; Sell S
Hepatology; 1998 Apr; 27(4):967-73. PubMed ID: 9537435
[TBL] [Abstract][Full Text] [Related]
14. Reduced hepatocyte proliferation is the basis of retarded liver tumor progression and liver regeneration in mice lacking N-acetylglucosaminyltransferase III.
Yang X; Tang J; Rogler CE; Stanley P
Cancer Res; 2003 Nov; 63(22):7753-9. PubMed ID: 14633700
[TBL] [Abstract][Full Text] [Related]
15. CCAAT/enhancer binding protein alpha knock-in mice exhibit early liver glycogen storage and reduced susceptibility to hepatocellular carcinoma.
Tan EH; Hooi SC; Laban M; Wong E; Ponniah S; Wee A; Wang ND
Cancer Res; 2005 Nov; 65(22):10330-7. PubMed ID: 16288022
[TBL] [Abstract][Full Text] [Related]
16. Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model.
Jin M; Saekusa Y; Dewa Y; Nishimura J; Matsumoto S; Shibutani M; Hasumi K; Mitsumori K
Arch Toxicol; 2009 Feb; 83(2):173-81. PubMed ID: 18597072
[TBL] [Abstract][Full Text] [Related]
17. Ploidy and karyotypic alterations associated with early events in the development of hepatocarcinogenesis in transgenic mice harboring c-myc and transforming growth factor alpha transgenes.
Sargent LM; Sanderson ND; Thorgeirsson SS
Cancer Res; 1996 May; 56(9):2137-42. PubMed ID: 8616862
[TBL] [Abstract][Full Text] [Related]
18. Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.
Huang X; Yu C; Jin C; Yang C; Xie R; Cao D; Wang F; McKeehan WL
Mol Carcinog; 2006 Dec; 45(12):934-42. PubMed ID: 16929488
[TBL] [Abstract][Full Text] [Related]
19. Tbx3 is a downstream target of the Wnt/beta-catenin pathway and a critical mediator of beta-catenin survival functions in liver cancer.
Renard CA; Labalette C; Armengol C; Cougot D; Wei Y; Cairo S; Pineau P; Neuveut C; de Reyniès A; Dejean A; Perret C; Buendia MA
Cancer Res; 2007 Feb; 67(3):901-10. PubMed ID: 17283120
[TBL] [Abstract][Full Text] [Related]
20. High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice.
Iwai S; Murai T; Makino S; Min W; Morimura K; Mori S; Hagihara A; Seki S; Fukushima S
Cancer Lett; 2007 Feb; 246(1-2):115-21. PubMed ID: 16569478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
